Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme

NCT02285959 is registered in ClinicalTrials.gov with Global Neurosciences Institute as lead sponsor.

NCT NCT02285959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Lead sponsor
Global Neurosciences Institute
Phase
Phase 1
Overall status
Unknown status
Start date
June 30, 2014
Completion date
June 30, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme